RT Journal Article
SR Electronic
T1 SARS-CoV-2 Seroprevalence Among Parturient Women
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.08.20149179
DO 10.1101/2020.07.08.20149179
A1 Dustin D. Flannery
A1 Sigrid Gouma
A1 Miren B. Dhudasia
A1 Sagori Mukhopadhyay
A1 Madeline R. Pfeifer
A1 Emily C. Woodford
A1 Jeffrey S. Gerber
A1 Claudia P. Arevalo
A1 Marcus J. Bolton
A1 Madison E. Weirick
A1 Eileen C. Goodwin
A1 Elizabeth M. Anderson
A1 Allison R. Greenplate
A1 Justin Kim
A1 Nicholas Han
A1 Ajinkya Pattekar
A1 Jeanette Dougherty
A1 Oliva Kuthuru
A1 Divij Mathew
A1 Amy E. Baxter
A1 Laura A. Vella
A1 JoEllen Weaver
A1 Anurag Verma
A1 Rita Leite
A1 Jeffrey S. Morris
A1 Daniel J. Rader
A1 Michal A. Elovitz
A1 E. John Wherry
A1 Karen M. Puopolo
A1 Scott E. Hensley
YR 2020
UL http://medrxiv.org/content/early/2020/07/10/2020.07.08.20149179.abstract
AB Limited data are available for pregnant women affected by SARS-CoV-2. Serological tests are critically important to determine exposure and immunity to SARS-CoV-2 within both individuals and populations. We completed SARS-CoV-2 serological testing of 1,293 parturient women at two centers in Philadelphia from April 4 to June 3, 2020. We tested 834 pre-pandemic samples collected in 2019 and 15 samples from COVID-19 recovered donors to validate our assay, which has a ∼1% false positive rate. We found 80/1,293 (6.2%) of parturient women possessed IgG and/or IgM SARS-CoV-2-specific antibodies. We found race/ethnicity differences in seroprevalence rates, with higher rates in Black/non-Hispanic and Hispanic/Latino women. Of the 72 seropositive women who also received nasopharyngeal polymerase chain reaction testing during pregnancy, 46 (64%) were positive. Continued serologic surveillance among pregnant women may inform perinatal clinical practices and can potentially be used to estimate seroprevalence within the community.One Sentence Summary Six percent of pregnant women delivering from April 4 to June 3, 2020 had serological evidence of exposure to SARS-CoV-2 with notable race/ethnicity differences in seroprevalence rates.Competing Interest StatementSEH has received consultancy fee from Sanofi Pasteur, Lumen, Novavax, and Merck for work unrelated to this report. EJW is a member of the Parker Institute for Cancer Immunotherapy. EJW has consulting agreements with and/or is on the scientific advisory board for Merck, Roche, Pieris, Elstar, and Surface Oncology. EJW is a founder of Surface Oncology and Arsenal Biosciences. EJW has a patent licensing agreement on the PD-1 pathway with Roche/Genentech. All other authors declare no competing interests related to this work.Clinical Trialresidual samples used, no trial IDFunding StatementThis work was supported by institutional funds from the University of Pennsylvania and an NIH grant AI082630 (to E.J.W.). We thank Jeffrey Lurie and we thank Joel Embiid, Josh Harris, David Blitzer for philanthropic support. E.J.W. is supported by the Parker Institute for Cancer Immunotherapy which supports the cancer immunology program at UPenn.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The Institutional Review Board at the University of Pennsylvania approved this study with waiver of consent.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data are included in the manuscript.